FDA approves acoramidis to treat ATTR-CM
The FDA says the drug is designed to reduce death and hospitalizations related to transthyretin cardiac amyloidosis (ATTR-CM).
News
-
-
Research suggests arginine holds prophylactic potential for patients at risk for ATTR-CM
Arginine helped stabilize TTR tetramers and prevented amyloid formation, showing its potential as a safe way to stave off ATTR-CM.
-
Sodium-glucose cotransporter-2 inhibitors could be useful for people with ATTR-CM
SGLT2is appeared to be safe for patients with ATTR-CM and may result in fewer hospitalizations and improved kidney function.
-
Study finds variability in signs of heart failure in patients with ATTR-CM
The study results highlighted the need to broaden diagnostic criteria for transthyretin amyloid cardiomyopathy, or ATTR-CM.